08:08 AM EST, 12/04/2024 (MT Newswires) -- Theratechnologies ( THTX ) on Wednesday said it has licensed two investigational RNA-targeted medicines developed by Ionis Pharmaceuticals.

Under the agreement, Theratechnologies ( THTX ) receives exclusive rights in Canada for olezarsen, which is being evaluated for familial chylomicronemia syndrome, and severe hypertriglyceridemia, and for donidalorsen, which is being evaluated for the treatment of hereditary angioedema.

Both medicines have been accepted by the U.S. Food and Drug Administration for review. Theratechnologies ( THTX ) plans to submit olezarsen and donidalorsen to Health Canada for review next year.

Ionis will receive a US$10 million upfront payment and milestone payments of up to US$12.75 million as well as tiered double-digit royalties on annual net sales of each medicine.

Theratechnologies ( THTX ) was last seen up US$0.04, to US$1.36, in U.S. premarket trade.